PADCEV

all catalysts(0)

nothing on the calendar yet

News(10)

• Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
  Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
  fiercebiotech · 1mo ago
• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 1mo ago
• Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
  The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…
  biospace · 2mo ago
• ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
  For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…
  fiercebiotech · 2mo ago
• Agenus surges on study pivot; Apnimed lines up an IPO
  Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
  biopharma_dive · 2mo ago
• Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
  Plus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…
  endpoints · 2mo ago
• Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
  Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
  biopharma_dive · 4mo ago
• AstraZeneca follows Merck with Phase 3 win in bladder cancer
  A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…
  endpoints · 4mo ago
• GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
  We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
  onclive · 4mo ago
• Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
  Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.
  onclive · 5mo ago